Source:http://linkedlifedata.com/resource/pubmed/id/12951482
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2003-9-2
|
pubmed:abstractText |
In this study, the role of interleukin (IL)-12 on the antimetastatic effect of Z-100 was investigated using wild-type C57BL/6 mice or IL-12p40 knockout (IL-12p40 KO) mice inoculated with highly metastatic B16F10 melanoma. When C57BL/6 mice were inoculated with B16F10 melanoma (2x10(5) cells/mouse i.v.), Z-100 (10 mg/kg i.p.) significantly suppressed the pulmonary metastasis of B16F10 melanoma 14 d after tumor inoculation. On the other hand, the antimetastatic effect of Z-100 was not observed in IL-12p40 KO mice inoculated with B16F10 melanoma. These results indicate that IL-12 is essentially required for the appearance of the antimetastatic effect of Z-100. Since helper T (Th) 2 cell responses have been reported to have a role in tumor metastasis, the regulatory effect of Z-100 on the immune balance of Th1/Th2 cell responses was investigated. In both C57BL/6 mice and IL-12p40 KO mice bearing B16F10 melanoma, Th1 cytokine production (IL-2, interferon-gamma) was significantly suppressed as compared with those in normal mice. On the other hand, Th2 cytokine production (IL-4, IL-10) in these mice was increased. The administration of Z-100 (10 mg/kg i.p.) in C57BL/6 mice bearing B16F10 melanoma improved the balance of Th1/Th2 cell responses from the Th2-dominant state to the normal state. However, the improvement of Th1/Th2 cell responses by Z-100 was not observed in IL-12p40 KO mice bearing the same tumors. In addition, Z-100 significantly increased IL-12 production by macrophages in a concentration-dependent manner, while Z-100 significantly decreased IL-10 production by these cells in vitro. These results suggested that up-regulation of IL-12 production and down-regulation of IL-10 production by Z-100 are related to the improvement of Th1/Th2 cell responses from the Th2-dominant state to the normal state, which resulted in suppression of tumor metastasis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Indicators and Reagents,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Mannans,
http://linkedlifedata.com/resource/pubmed/chemical/arabinomannan,
http://linkedlifedata.com/resource/pubmed/chemical/specific substance maruyama
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0918-6158
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1336-41
|
pubmed:dateRevised |
2006-7-27
|
pubmed:meshHeading |
pubmed-meshheading:12951482-Adjuvants, Immunologic,
pubmed-meshheading:12951482-Animals,
pubmed-meshheading:12951482-Antineoplastic Agents,
pubmed-meshheading:12951482-Indicators and Reagents,
pubmed-meshheading:12951482-Interleukin-12,
pubmed-meshheading:12951482-Lipids,
pubmed-meshheading:12951482-Mannans,
pubmed-meshheading:12951482-Melanoma, Experimental,
pubmed-meshheading:12951482-Mice,
pubmed-meshheading:12951482-Mice, Inbred C57BL,
pubmed-meshheading:12951482-Mice, Knockout,
pubmed-meshheading:12951482-Mycobacterium bovis,
pubmed-meshheading:12951482-Mycobacterium tuberculosis,
pubmed-meshheading:12951482-Neoplasm Metastasis,
pubmed-meshheading:12951482-Neoplasm Transplantation,
pubmed-meshheading:12951482-Th1 Cells,
pubmed-meshheading:12951482-Th2 Cells
|
pubmed:year |
2003
|
pubmed:articleTitle |
Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12.
|
pubmed:affiliation |
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Ohsato-gun, Saitama, Japan. hideki-oka@zeria.co.jp
|
pubmed:publicationType |
Journal Article
|